Xiujuan Wu

Southwest Hospital

Papers

1

Total Citations

50

H-Index

1

About

Dr. Xiujuan Wu is a leading breast cancer surgeon whose work is reshaping the surgical landscape of oncology. Her primary research focuses on the comparative effectiveness of minimal access breast surgery (MABS) versus conventional breast surgery (CBS), a critical area where long-term prognostic data were previously scarce. Dr. Wu’s landmark 2022 study, which has garnered 50 citations, directly addressed this gap by providing robust evidence on the long-term oncologic outcomes associated with these techniques. Her findings are pivotal, demonstrating that MABS can achieve therapeutic results comparable to CBS, thereby offering patients less invasive options without compromising survival. This contribution has significant implications for clinical practice, potentially reducing surgical morbidity and improving quality of life for breast cancer patients. By systematically evaluating the trade-offs between cosmetic preservation and oncologic safety, Dr. Wu has established herself as a key voice in evidence-based surgical decision-making. Her work not only informs current guidelines but also sets the stage for future trials, solidifying her reputation as a researcher dedicated to advancing patient-centered, minimally invasive cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
50
Total Citations
50
Avg Citations/Paper
🏆 Most Cited Paper
Association of Long-term Oncologic Prognosis With Minimal Access Breast Surgery vs Conventional Breast Surgery
50 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Southwest Hospital

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago